PacBio to Increase MAS-Seq Engineering to 16S rRNA and Bulk RNA-Seq Solutions

Conclude-to-Stop Alternatives Prepared to Guidance Crucial Shopper Applications With Enhanced Cost Flexibility on Lengthy-Study Sequencing Systems

MENLO PARK, Calif., Feb. 7, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a top developer of significant-high-quality, remarkably correct sequencing alternatives, these days announced the commencement of a method intended to expand Multiplexed Arrays Sequencing (MAS-Seq) for new assays on the Sequel II/IIe and Revio™ sequencing systems. This plan builds on the effective MAS-Seq concatenation technology introduced past year that enabled price-successful solitary-cell isoform sequencing.


(PRNewsfoto/Pacific Biosciences of California, Inc.)

The MAS-Seq engineering concatenates multiple shorter fragments which are then study on the system as just one prolonged HiFi examine. This extends the efficient throughput by up to 16-fold, where the throughput boost component is decided by the dimensions of the quick fragment. We believe that that extending MAS-Seq engineering to essential purposes such as bulk RNA sequencing and 16S rRNA will provide buyers with price-successful kitted alternatives and stop-to-stop program.

“Due to the fact our Oct announcement of the first MAS-Seq based mostly kit, the consumer need has been really encouraging, to the level that buyers have been asking us to grow the technologies to their beloved software,” reported Christian Henry, President and Chief Govt Officer at PacBio. “We imagine making use of MAS-Seq technological know-how to these purposes will aid deepen our knowing of biology. In RNA sequencing reports, for example, MAS-Seq will enable shift the area to real transcriptomics research. We are tremendously psyched to develop on the momentum of MAS-Seq to open new alternatives in Bulk RNA-Seq and 16S rRNA experiments for our customers.”

“We are excited that PacBio is addressing the unmet require for more expense-helpful complete-duration RNA sequencing,” mentioned Jeremy Schmutz, Ph.D., co-director of the HudsonAlpha Genome Sequencing Center. “HudsonAlpha works by using PacBio’s Iso-Seq method (whole-length RNA sequencing) for enhanced genome annotations and practical study. The new MAS-Seq kits for bulk Iso-Seq, mixed with the envisioned raise in Revio’s throughput, will empower slicing edge investigation in human, plant and animal genomics.”

PacBio intends to start this 1st expanded sequence of MAS-Seq kits in the second 50 % of 2023. PacBio plans to share early information and a specialized overview to interested events at this week’s Improvements in Genome Biology and Technological know-how (AGBT) Basic Conference getting area February 6-9, 2023 in Hollywood, FL.

About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier lifetime science technological innovation firm that is building, developing and producing advanced sequencing solutions to assistance scientists and medical scientists take care of genetically complicated troubles. Our items and know-how underneath growth stem from two highly differentiated core technologies targeted on precision, high quality and completeness which involve our current HiFi long read through sequencing and our rising SBB™ shorter-read through sequencing systems. Our solutions handle remedies across a wide established of investigate apps like human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other rising apps. For additional information, please visit www.pacb.com and stick to @PacBio.

PacBio products and solutions are delivered for Exploration Use Only. Not for use in diagnostic procedures.

Forward-Searching Statements
This push launch has “ahead-looking statements” in the which means of Area 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are ahead-on the lookout statements, such as statements relating to future availability, release time-frames, employs, accuracy, benefits, high-quality or efficiency of, or benefits or expected rewards of employing, PacBio items or technologies, which includes with regard to the opportunity expansion of MAS-Seq technological know-how to new assays for use on the Sequel II/IIe and Revio programs offering price tag-powerful kitted-solutions and finish-to-conclusion software package by extending the MAS-Seq technology strategies to launch the expanded MAS-Seq kits in the next half of 2023 and share early info and a specialized overview at AGBT ability to open new chances for customers by extending the opportunity breakthroughs for people that could end result from the use of Twist Alliance panels and PacBio engineering capacity of MAS-Seq kits and Revio to allow cutting edge exploration in human, plant and animal genomics collaborations to display SBB precision and other forward-searching statements. Visitors are cautioned not to spot undue reliance on these ahead-hunting statements and any these kinds of ahead-on the lookout statements are competent in their entirety by reference to the following cautionary statements. All forward-wanting statements communicate only as of the date of this push release and are based mostly on present-day expectations and contain a amount of assumptions, challenges and uncertainties that could bring about the real results to vary materially from these types of ahead-wanting statements, which include, among the some others, troubles inherent in establishing, manufacturing, launching, promoting and advertising new solutions, and reaching expected new profits assumptions, risks and uncertainties associated to the means to attract new shoppers and retain and increase income from present clients possible item functionality and high quality difficulties and opportunity delays in commercialization timelines speedily shifting technologies and considerable competitors in genomic sequencing that could make the solutions PacBio is acquiring out of date or non-competitive source chain dangers correctly finishing growth of a solution that is not still commercially obtainable prospects and possible prospects curtailing or suspending pursuits employing our items the affect of U.S. export limits on the cargo of PacBio solutions to specified countries and third-social gathering statements alleging infringement of patents and proprietary rights or trying to find to invalidate PacBio’s patents or proprietary rights. Viewers are strongly inspired to read the full cautionary statements contained in PacBio’s filings with the Securities and Exchange Commission, such as the hazards set forth in the company’s Types 8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or revise any forward-searching statements.

Make contact with:

Traders:
Todd Friedman
[email protected]

Media:
Lizelda Lopez
[email protected]

Source Pacific Biosciences of California, Inc.

Related posts